CAR-T therapy transforms relapsed lymphoma into a race for treatment access
CAR-T therapy offers a lifeline for patients with relapsed blood cancers, but the real challenge is getting the treatment before time and logistics run out.
Kymriah 1 article
Kymriah is the specific therapeutic product associated with tisagenlecleucel and CD19-directed CAR T-cell therapy. Its biological design brings together autologous T cells, 4-1BB costimulatory domain and chimeric antigen receptor, while B-cell malignancy therapy, acute lymphoblastic leukemia and diffuse large B-cell lymphoma define the disease, delivery or mechanistic context in which the intervention is understood. That scope preserves Kymriah as a product-level entity rather than a synonym for CD19-directed CAR T-cell therapy.